Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00006228
What this trial is testing

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Testing effectiveness (Phase 2)Looking for participantsNCT06533826
What this trial is testing

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Who this might be right for
Breast CancerHER2-low Breast CancerMetastatic Breast Cancer+1 more
Ana C Garrido-Castro, MD 357
Not applicableNot Yet RecruitingNCT07130344
What this trial is testing

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

Who this might be right for
Metastatic Breast CancerHER 2 Low-expressing Breast Cancer
Centre Paul Strauss 262
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Not applicableEnded earlyNCT05592483
What this trial is testing

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 78
Not applicableLooking for participantsNCT05573893
What this trial is testing

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Who this might be right for
Breast NeoplasmsBreast CancerNeoplasm Metastasis
AstraZeneca 800
Large-scale testing (Phase 3)Looking for participantsNCT05950945
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Daiichi Sankyo 250
Testing effectiveness (Phase 2)Study completedNCT02048059
What this trial is testing

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Who this might be right for
Breast CancerBrain Metastases
Angiochem Inc 72
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Looking for participantsNCT06642545
What this trial is testing

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 40
Not applicableStudy completedNCT04807595
What this trial is testing

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Who this might be right for
Breast Cancer
AstraZeneca 798
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Testing effectiveness (Phase 2)UnknownNCT04742153
What this trial is testing

MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Who this might be right for
Advanced or Metastatic Breast Cancer
Shanghai Miracogen Inc. 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Testing effectiveness (Phase 2)UnknownNCT05619016
What this trial is testing

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Who this might be right for
Esophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more
Karolinska University Hospital 72
Not applicableLooking for participantsNCT06830382
What this trial is testing

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

Who this might be right for
Breast Cancer Stage IVHER2-low Breast CancerMolecular Imaging
Renske Altena 70
Early research (Phase 1)Looking for participantsNCT06331169
What this trial is testing

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 42
Testing effectiveness (Phase 2)Study completedNCT02491892
What this trial is testing

Pertuzumab in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 79
Testing effectiveness (Phase 2)Looking for participantsNCT06665178
What this trial is testing

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 20
Next Page